AbbVie Inc (ABBV)vsTriSalus Life Sciences Inc. (TLSI)
ABBV
AbbVie Inc
$227.23
+0.40%
HEALTHCARE · Cap: $391.50B
TLSI
TriSalus Life Sciences Inc.
$3.30
+3.77%
HEALTHCARE · Cap: $223.56M
Smart Verdict
WallStSmart Research — data-driven comparison
AbbVie Inc generates 139862% more annual revenue ($62.82B vs $44.88M). ABBV leads profitability with a 5.8% profit margin vs -60.9%. ABBV earns a higher WallStSmart Score of 63/100 (C+).
ABBV
Buy63
out of 100
Grade: C+
TLSI
Avoid16
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-52.4%
Fair Value
$146.00
Current Price
$227.23
$81.23 premium
Intrinsic value data unavailable for TLSI.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 62 in profit
Strong operational efficiency at 32.2%
Conservative balance sheet, low leverage
Growing faster than its price suggests
Generating 3.6B in free cash flow
No standout strengths identified
Areas to Watch
5.8% margin — thin
Premium valuation, high expectations priced in
Earnings declined 46.2%
Distress zone — elevated risk
Trading at 15.7x book value
0.0% earnings growth
Smaller company, higher risk/reward
ROE of -496.2% — below average capital efficiency
Comparative Analysis Report
WallStSmart ResearchBull Case : ABBV
The strongest argument for ABBV centers on Market Cap, Return on Equity, Operating Margin. Revenue growth of 12.4% demonstrates continued momentum. PEG of 0.61 suggests the stock is reasonably priced for its growth.
Bull Case : TLSI
TLSI has a balanced fundamental profile.
Bear Case : ABBV
The primary concerns for ABBV are Profit Margin, P/E Ratio, EPS Growth. A P/E of 108.6x leaves little room for execution misses.
Bear Case : TLSI
The primary concerns for TLSI are Price/Book, EPS Growth, Market Cap. Debt-to-equity of 2.69 is elevated, increasing financial risk.
Key Dynamics to Monitor
ABBV profiles as a value stock while TLSI is a turnaround play — different risk/reward profiles.
TLSI carries more volatility with a beta of 0.49 — expect wider price swings.
ABBV is growing revenue faster at 12.4% — sustainability is the question.
ABBV generates stronger free cash flow (3.6B), providing more financial flexibility.
Bottom Line
ABBV scores higher overall (63/100 vs 16/100) and 12.4% revenue growth. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
AbbVie Inc
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
AbbVie is an American publicly traded biopharmaceutical company founded in 2013. It originated as a spin-off of Abbott Laboratories.
TriSalus Life Sciences Inc.
HEALTHCARE · MEDICAL DEVICES · USA
TriSalus Life Sciences Inc. (TLSI) is an innovative biopharmaceutical company focused on revolutionizing cancer treatment through its proprietary localized drug delivery systems. By enhancing the effectiveness of immuno-oncology agents and overcoming distribution challenges within tumor microenvironments, TriSalus is dedicated to improving therapeutic outcomes for cancer patients. With a promising pipeline of clinical programs, the company aims to meet the urgent demand for advanced cancer therapies. Positioned strategically within the dynamic oncology landscape, TriSalus is poised for significant impact as it seeks to expand access to its groundbreaking treatments.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?